Evidence map›Paper›PMID 30102868›Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2018

Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer.

Sze Huey Tan, Keith R Abrams, Sylwia Bujkiewicz

Open access · hybridAbstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Classifying information-sharing methods.BMC medical research methodology · 2021
    Article
  3. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Sze Huey TanBiostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, UK (SHT, KRA, SB).
Keith R AbramsBiostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, UK (SHT, KRA, SB).
Sylwia BujkiewiczBiostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, UK (SHT, KRA, SB).
University of Leicester · GBNational Cancer Centre Singapore · SG

Funding

Department of Health NF-SI-0512-10159Medical Research Council MR/L009854/1
6 · The paper itself

Abstract

In health technology assessment, decisions are based on complex cost-effectiveness models that require numerous input parameters. When not all relevant estimates are available, the model may have to be simplified. Multiparameter evidence synthesis combines data from diverse sources of evidence, which results in obtaining estimates required in clinical decision making that otherwise may not be available. We demonstrate how bivariate meta-analysis can be used to predict an unreported estimate of a treatment effect enabling implementation of a multistate Markov model, which otherwise needs to be simplified. To illustrate this, we used an example of cost-effectiveness analysis for docetaxel in combination with prednisolone in metastatic hormone-refractory prostate cancer. Bivariate meta-analysis was used to model jointly available data on treatment effects on overall survival and progression-free survival (PFS) to predict the unreported effect on PFS in a study evaluating docetaxel with prednisolone. The predicted treatment effect on PFS enabled implementation of a 3-state Markov model comprising stable disease, progressive disease, and dead states, while lack of the estimate restricted the model to a 2-state model (with alive and dead states). The 2-state and 3-state models were compared by calculating the incremental cost-effectiveness ratio (which was much lower in the 3-state model: £22,148 per quality-adjusted life year gained compared to £30,026 obtained from the 2-state model) and the expected value of perfect information (which increased with the 3-state model). The 3-state model has the advantage of distinguishing surviving patients who progressed from those who did not progress. Hence, the use of advanced meta-analytic techniques allowed obtaining relevant parameter estimates to populate a model describing disease pathway in more detail while helping to prevent valuable clinical data from being discarded.

Indexed as

Bayes TheoremClinical Decision-MakingMeta-Analysis as TopicNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantCost-Benefit AnalysisDisease-Free SurvivalHumansMaleRandomized Controlled Trials as Topicbivariate meta-analysisMarkov multi-state modelprostate cancer

Identifiers

PMID30102868
PMCPMC6156771
OpenAlexW2617381319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.